Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients

Phase 2

Terminated

Conditions: Ewing's Sarcoma

Interventions: Drug: Vincristine
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Dexrazoxane
Biological: ImmTher

First Posted Date: 2002-05-30

Last Posted Date: 2020-01-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00038142

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia

Phase 2

Completed

Conditions: Hematologic Diseases
Beta-Thalassemia
Hematopoietic Stem Cell Transplantation
Anemia, Sickle Cell

First Posted Date: 2002-01-11

Last Posted Date: 2016-07-29

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 30

Registration Number: NCT00029380

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
Children's Hospital, Oakland, Oakland, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 12 locations

Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 33

Registration Number: NCT00000801

Locations: 🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸
San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸
San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States

and more 4 locations

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: HIV Infections
Lymphoma, Non-Hodgkin

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 250

Registration Number: NCT00000658

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Ucsf Aids Crs, San Francisco, California, United States

and more 19 locations

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

Not Applicable

Completed

Conditions: Lymphoma, Non-Hodgkin
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT00000703

Locations: 🇺🇸
Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸
Milton S Hershey Med Ctr, Hershey, Pennsylvania, United States

and more 11 locations

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT00000689

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT00000899

Locations: 🇺🇸
Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Duke Univ Med Ctr, Durham, North Carolina, United States

Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus

Phase 1

Conditions: Systemic Lupus Erythematosus

First Posted Date: 2001-06-06

Last Posted Date: 2005-06-24

Lead Sponsor: Northwestern Memorial Hospital

Target Recruit Count: 10

Registration Number: NCT00017641

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis

Phase 1

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2001-06-06

Last Posted Date: 2005-06-24

Lead Sponsor: Northwestern Memorial Hospital

Target Recruit Count: 20

Registration Number: NCT00017628

Locations: 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia

Not Applicable

Conditions: Graft Versus Host Disease
Aplastic Anemia

First Posted Date: 2001-06-06

Last Posted Date: 2005-06-24

Lead Sponsor: Northwestern Memorial Hospital

Target Recruit Count: 3

Registration Number: NCT00017654

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy